# US 2003/0069199 A1 · Treatment methods based on microcompetition for a limiting GABP complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069199 A1
- Document ID: US20030069199A1
- Status: Published application
- Kind: A1
- Application number: 10/219,334
- Filed: 2002-08-15
- Published: 2003-04-10
- Earliest claimed: 2000-12-07
- Inventors: Hanan Polansky
- Web page: https://patentgrep.com/patent/US20030069199A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor associated with chronic disease such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present methods for the treatment of these chronic diseases. The methods are based on modifying such microcompetition, or the effect of such microcompetition on the cell. For instance, treatment may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between GABP and either the foreign polynucleotide or the cellular GABP regulated gene, vary the expression of the cellular GABP regulated gene, or manipulate the activity of the gene product of the cellular GABP regulated gene. The invention also presents methods for treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

## Claims

### Claim 1

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent that modifies microcompetition for GABP between a polynucleotide natural to said subject and a polynucleotide foreign to said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said polynucleotide foreign to said subject is a viral promoter or viral enhancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein said foreign polynucleotide is the complete, or a fragment of the genome of a GABP virus.

### Claim 4 (depends on 1)

The method of claim 1, wherein said polynucleotide foreign to said subject is selected from a group consisting of: a promoter of a GABP virus, an enhancer of a GABP virus, and a viral polynucleotide that includes an N-box.

### Claim 5 (depends on 1)

The method of claim 1, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 6

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent that modifies formation of a complex that includes GABP and a polynucleotide foreign to said subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein said polynucleotide foreign to said subject is a viral promoter or viral enhancer.

### Claim 8 (depends on 6)

The method of claim 6, wherein said foreign polynucleotide is the complete, or a fragment of the genome of a GABP virus.

### Claim 9 (depends on 6)

The method of claim 6, wherein said polynucleotide foreign to said subject is selected from a group consisting of: a promoter of a GABP virus, an enhancer of a GABP virus, and a viral polynucleotide that includes an N-box.

### Claim 10 (depends on 6)

The method of claim 6, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 11

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent that modifies formation of a complex that includes GABP and a polynucleotide natural to said subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein said polynucleotide natural to said subject is a GABP regulated gene, or a fragment of a GABP regulated gene.

### Claim 13 (depends on 11)

The method of claim 11, wherein said polynucleotide foreign to said subject is a viral polynucleotide that includes an N-box.

### Claim 14 (depends on 11)

The method of claim 11, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 15

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent that modifies the copy number of a GABP polynucleotide foreign to said subject, in a said subject cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein said polynucleotide foreign to said subject is selected from the group consisting of: a promoter of a GABP virus, an enhancer of a GABP virus, and a viral polynucleotide that includes an N-box.

### Claim 17 (depends on 15)

The method of claim 15, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 18

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent that modifies the copy number of a latent GABP polynucleotide foreign to said subject, in a said subject cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein said polynucleotide foreign to said subject is selected from a group consisting of: a promoter of a GABP virus, an enhancer of a GABP virus, and a viral polynucleotide that includes an N-box.

### Claim 20 (depends on 18)

The method of claim 18, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 21

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent which performs a function selected from a group consisting of:
a) increases concentration of GABPα;
b) increases concentration of GABPβ;
c) decreases concentration of GABPγ;
d) increases phosphorylation of GABP;
e) modifies affinity or avidity between members of the GABP family of proteins;
f) increases affinity or avidity between GABP and p300/cbp;
g) increases concentration of p300/cbp.

### Claim 22 (depends on 21)

The method of claim 21, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 23

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent which performs a function selected from a group consisting of:
a) modifies expression of a GABP regulated gene;
b) modifies activity of a gene product of a GABP regulated gene.

### Claim 24 (depends on 23)

The method of claim 23, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.

### Claim 25

A method for the treatment of a chronic disease, comprising administration to an animal or human subject an effective amount of an agent which performs a function selected from a group consisting of:
a) increases concentration of a GABP kinase;
b) stimulates phosphorylation of a GABP kinase;
c) decreases concentration of a GABP phosphatase;
d) inhibits phosphorylation of a GABP phosphatase;
e) increases affinity or avidity between GABP and a GABP kinase;
f) decreases affinity or avidity between GABP and a GABP phosphatase;
g) decreases oxidative effects on GABP.

### Claim 26 (depends on 25)

The method of claim 25, wherein said chronic disease is selected from the group consisting of obesity, cancer, atherosclerosis, stroke, osteoarthritis, type II diabetes, type I diabetes, asthma, lupus, multiple sclerosis, and other autoimmune diseases.
